Analyses of kidney outcomes in the original CVOTs prompted dedicated kidney outcome trials, of which two are completed: Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy (CREDENCE, NCT02065791) and A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease (DAPA-CKD, NCT03036150)
Microenvironment remodeling micelles for Alzheimers disease therapy by early modulation of activated microglia
May also contain light spine creasing or a few markings such as an owner's name, short gifter's inscription or light stamp
Advanced experimental models integrating vascular remodeling, BBB integrity, and neurovascular interactions are essential to accurately simulate the dynamics of chronic disease
N -(2-aminoethyl)acrylamide 3a
Recalls & Warnings January 09, 2014 Four Companies Settle FTC Charges of Deceptive Weight Loss Claims On January 7, 2014, the Federal Trade Commission (FTC) announced that marketers for four weight loss products have agreed to settlements over charges of deceptive weight loss claims
